Clene Inc (CLNN)

$5.32 -0.09 (-1.66%)
Market Cap 53.15M
Revenue (ttm) 340,000.00
Net Income (ttm) -39.40M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11,588.24%
Debt to Equity Ratio -0.54
Volume 33,700
Avg Vol 74,388
Day's Range N/A - N/A
Shares Out 9.99M
Stochastic %K 76%
Beta 0.55
Analysts Strong Sell
Price Target $30.71

Company Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; comp...

Industry: Packaged Foods
Sector: Consumer Defensive
Phone: 801 676 9695
Website: clene.com
Address:
6550 South Millrock Drive, Suite G50, Salt Lake City, United States
fibonacci1170
fibonacci1170 Aug. 30 at 9:38 PM
$CLNN NfL data analysis will officially begin on 1 Sept. Clene will get the final results from quanterix latest by 30 Sept. Then another ~15 days to announce the results publicly. We will have NfL PR by 15 Oct. Could come sooner if quanterix finishes data analysis sooner. This is it folks. Hoping for a new ALS drug and 100x return on investment 🤞
0 · Reply
NetworkNewsWire
NetworkNewsWire Aug. 29 at 7:09 PM
InvestorNewsBreaks – $CLNN Builds Late-Stage Momentum in Neuro Pipeline https://ibn.fm/zCW6r
0 · Reply
GenX420
GenX420 Aug. 29 at 2:37 PM
$CLNN glad to see that we are holding in this range. That was a pretty violent drop in after-hours trading yesterday.
1 · Reply
Acx21
Acx21 Aug. 29 at 8:26 AM
$CLNN he's just frustrated about having sold his shares with a loss - stupidly enough to hold for year just to sell a short time before the important information will be released. Anyways, don't just call a random target, give us some information about your calculation
1 · Reply
Impatient_Investor
Impatient_Investor Aug. 29 at 6:05 AM
$CLNN
1 · Reply
Mulhollandr
Mulhollandr Aug. 29 at 3:38 AM
$CLNN might have found the source of our spike from the 18th. She has 56k followers. 🤔
1 · Reply
Scoops1212
Scoops1212 Aug. 29 at 12:46 AM
$CLNN
0 · Reply
fibonacci1170
fibonacci1170 Aug. 28 at 7:39 PM
$CLNN both cder and cber are rejecting drugs willy nilly saying "lack of substantial evidence for efficacy". Even if NfL data is robust, what are the chances this FDA will not renege on its promise of accelerated approval? I will hold my shares because the upside is outrageous, but in general it seems like biotech has become too risky to invest in with such a hostile FDA. These hardcore slaves of science can't seem to look past p-values. Any thoughts?..
1 · Reply
Mulhollandr
Mulhollandr Aug. 26 at 2:19 PM
$CLNN bull flag
2 · Reply
Mulhollandr
Mulhollandr Aug. 26 at 10:50 AM
$CLNN 5 weeks left in q3…FDA meetings could be happening at any point now.
0 · Reply
Latest News on CLNN
Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

Aug 14, 2025, 8:38 AM EDT - 16 days ago

Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

Clene to Present at the Emerging Growth Conference

Aug 13, 2025, 8:00 AM EDT - 17 days ago

Clene to Present at the Emerging Growth Conference

Clene to Present at the Canaccord 45th Annual Growth Conference

Aug 5, 2025, 8:30 AM EDT - 25 days ago

Clene to Present at the Canaccord 45th Annual Growth Conference

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

Jun 30, 2025, 8:00 AM EDT - 2 months ago

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

Jun 9, 2025, 9:00 AM EDT - 2 months ago

Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

May 7, 2025, 8:00 AM EDT - 4 months ago

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

Clene to Present at the Jones Healthcare and Technology Innovation Conference

Apr 1, 2025, 8:30 AM EDT - 5 months ago

Clene to Present at the Jones Healthcare and Technology Innovation Conference

Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

Mar 24, 2025, 8:00 AM EDT - 5 months ago

Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

Mar 12, 2025, 8:00 AM EDT - 6 months ago

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

Clene to Present at the 37TH Annual Roth Conference

Mar 6, 2025, 8:30 AM EST - 6 months ago

Clene to Present at the 37TH Annual Roth Conference

Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11

Feb 27, 2025, 9:15 AM EST - 6 months ago

Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11

Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction

Feb 25, 2025, 8:00 AM EST - 6 months ago

Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Dec 10, 2024, 8:30 AM EST - 9 months ago

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

Sep 30, 2024, 8:30 AM EDT - 11 months ago

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.

Aug 8, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

Aug 7, 2024, 8:23 AM EDT - 1 year ago

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

Jul 11, 2024, 9:00 AM EDT - 1 year ago

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

Clene Announces 1-for-20 Reverse Stock Split

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Clene Announces 1-for-20 Reverse Stock Split

Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference

Jun 24, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

Jun 21, 2024, 7:09 AM EDT - 1 year ago

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

Jun 18, 2024, 7:00 AM EDT - 1 year ago

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

May 28, 2024, 7:30 AM EDT - 1 year ago

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

Clene to Present at Upcoming May Conferences

May 14, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at Upcoming May Conferences

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

May 8, 2024, 8:00 AM EDT - 1 year ago

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

Apr 16, 2024, 4:01 PM EDT - 1 year ago

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Mar 13, 2024, 8:00 AM EDT - 1 year ago

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

Feb 29, 2024, 8:00 AM EST - 1 year ago

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

Clene says FDA finds ALS drug data not enough for accelerated nod

Dec 21, 2023, 11:25 AM EST - 1 year ago

Clene says FDA finds ALS drug data not enough for accelerated nod

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

Dec 21, 2023, 7:00 AM EST - 1 year ago

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

Clene Provides Update on ALS Clinical Development Meeting With FDA

Dec 21, 2023, 7:00 AM EST - 1 year ago

Clene Provides Update on ALS Clinical Development Meeting With FDA

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Dec 14, 2023, 8:36 AM EST - 1 year ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

Nov 7, 2023, 8:00 AM EST - 1 year ago

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Oct 5, 2023, 10:00 AM EDT - 2 years ago

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

Sep 25, 2023, 4:00 PM EDT - 2 years ago

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

Sep 25, 2023, 7:00 AM EDT - 2 years ago

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

Clene to Present at Upcoming September Conferences

Aug 30, 2023, 8:20 AM EDT - 2 years ago

Clene to Present at Upcoming September Conferences

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

Aug 29, 2023, 7:00 AM EDT - 2 years ago

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

Aug 2, 2023, 7:00 AM EDT - 2 years ago

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET's eClinicalMedicine

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET's eClinicalMedicine

Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million

Jun 21, 2023, 9:20 AM EDT - 2 years ago

Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million

Clene Announces Pricing of $40 Million Public Offering

Jun 16, 2023, 8:00 AM EDT - 2 years ago

Clene Announces Pricing of $40 Million Public Offering

Clene Announces Launch of Proposed Public Offering

Jun 15, 2023, 4:38 PM EDT - 2 years ago

Clene Announces Launch of Proposed Public Offering

Clene's CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial

Jun 15, 2023, 4:29 PM EDT - 2 years ago

Clene's CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial

Clene to Participate in the Maxim Group Virtual Healthcare Conference

Jun 15, 2023, 7:00 AM EDT - 2 years ago

Clene to Participate in the Maxim Group Virtual Healthcare Conference

Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights

May 12, 2023, 4:00 PM EDT - 2 years ago

Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights

fibonacci1170
fibonacci1170 Aug. 30 at 9:38 PM
$CLNN NfL data analysis will officially begin on 1 Sept. Clene will get the final results from quanterix latest by 30 Sept. Then another ~15 days to announce the results publicly. We will have NfL PR by 15 Oct. Could come sooner if quanterix finishes data analysis sooner. This is it folks. Hoping for a new ALS drug and 100x return on investment 🤞
0 · Reply
NetworkNewsWire
NetworkNewsWire Aug. 29 at 7:09 PM
InvestorNewsBreaks – $CLNN Builds Late-Stage Momentum in Neuro Pipeline https://ibn.fm/zCW6r
0 · Reply
GenX420
GenX420 Aug. 29 at 2:37 PM
$CLNN glad to see that we are holding in this range. That was a pretty violent drop in after-hours trading yesterday.
1 · Reply
Acx21
Acx21 Aug. 29 at 8:26 AM
$CLNN he's just frustrated about having sold his shares with a loss - stupidly enough to hold for year just to sell a short time before the important information will be released. Anyways, don't just call a random target, give us some information about your calculation
1 · Reply
Impatient_Investor
Impatient_Investor Aug. 29 at 6:05 AM
$CLNN
1 · Reply
Mulhollandr
Mulhollandr Aug. 29 at 3:38 AM
$CLNN might have found the source of our spike from the 18th. She has 56k followers. 🤔
1 · Reply
Scoops1212
Scoops1212 Aug. 29 at 12:46 AM
$CLNN
0 · Reply
fibonacci1170
fibonacci1170 Aug. 28 at 7:39 PM
$CLNN both cder and cber are rejecting drugs willy nilly saying "lack of substantial evidence for efficacy". Even if NfL data is robust, what are the chances this FDA will not renege on its promise of accelerated approval? I will hold my shares because the upside is outrageous, but in general it seems like biotech has become too risky to invest in with such a hostile FDA. These hardcore slaves of science can't seem to look past p-values. Any thoughts?..
1 · Reply
Mulhollandr
Mulhollandr Aug. 26 at 2:19 PM
$CLNN bull flag
2 · Reply
Mulhollandr
Mulhollandr Aug. 26 at 10:50 AM
$CLNN 5 weeks left in q3…FDA meetings could be happening at any point now.
0 · Reply
Scoops1212
Scoops1212 Aug. 26 at 4:27 AM
$CLNN
2 · Reply
josh77
josh77 Aug. 25 at 1:34 AM
$CLNN I'll buy more!! Ive held for a long time. I believe in the science and potential...patience!
1 · Reply
StockScanners
StockScanners Aug. 23 at 7:32 PM
$CLNN back near res from previous high of 5.78, lets go
0 · Reply
Mulhollandr
Mulhollandr Aug. 22 at 11:53 PM
$CLNN
0 · Reply
NetworkNewsWire
NetworkNewsWire Aug. 22 at 6:49 PM
Pioneering Therapy Could Slow the Effects of Aging $CLNN https://ibn.fm/WvRGB #biomedstocks #Aging
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Aug. 22 at 2:54 PM
$CLNN +116.15% last 3 months. That's nearly 40% per month for CLNN. I Own CLNNW.
0 · Reply
GJ_Rockabilt
GJ_Rockabilt Aug. 22 at 2:47 PM
$CLNN I reckon another Bull Flag has been raised. Put hand on heart. Sing.
0 · Reply
mrpsny
mrpsny Aug. 22 at 9:43 AM
$CLNN nice to see some positive price action here, but we've seen this before. It would be good to find some sort of support around $5 and hold as we await further news. Nice to know they can forecast into Q1 26, however, if AA isn't approved before then. Dilution time?. Either way, enjoy the ride.
1 · Reply
NetworkNewsWire
NetworkNewsWire Aug. 21 at 7:38 PM
$CLNN Reports Q2 2025 Results as Company Prepares for NDA Submission and Extends Runway into 2026 https://ibn.fm/aBteM
0 · Reply
Raxothus
Raxothus Aug. 21 at 6:44 PM
EOD FOLLOW-UP - 08/20/25 Tracking continuation watchlist from today based on intraday highs vs. close ❌ $CLNN - Closed 5.66, HOD 5.59 (–1.2%) Failed to push, straight fade. ❌ $MURA - No volume, no movement. ❌ $COCH - No volume, no movement. ✅ $NESR - Closed 8.31, HOD 8.81 (+6.0%) Brief pop, then dancing around the VWAP ❌ $GES - No volume, no movement. Recap: 5 total, 1 winners, 4 fails → 20% accuracy Almost no continuation strength today. $NESR gave a small pop but couldn’t hold, while $CLNN, $MURA, $COCH, and $GES showed no traction. #VWAP #SmallCaps #DayTrading #EODFollowUp #Continuation #SniperSetup #Accountability
0 · Reply
bosch49
bosch49 Aug. 21 at 4:41 PM
$CLNN I put a bunch of eggs here 🥚 🪺 should be a very exciting next 6 weeks I hope .
0 · Reply
LXP
LXP Aug. 21 at 4:40 PM
$CLNN fight my little Clene. Love it
0 · Reply